Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Swine Flu Daily Update Issued At: 11am Friday 3 July 2009, Wales
-- 37 confirmed cases in Wales, with 3 new cases:
generic viagra online
CBO Director May Help Determine Fate Of Health Care
Several newspapers had articles on major players in health care reform. Douglas W. Elmendorf, director of the Congressional Budget Office, has "toiled for much of his career in the anonymous bowels of the nation"s economic superstructure," the Washington Post reports. But now, some lawmakers "think he holds the fate of public policy in his hands." After delivering a "skeptical analysis of a stimulus package intended to rescue the U.S. economy" and forecasting "bigger-than-expected losses from a $700 billion bailout of the U.S. financial system, Elmendorf now "faces the toughest task of his brief tenure: attaching a price to a monumental overhaul of the nation"s health-care system." Sen. Max Baucus, D-Mont., has "publicly lectured Elmendorf, saying he has a moral duty to be "creative" and deliver the favorable budget estimates "we have to have" to win broad support." But Elmendorf says "his office will offer an objective analysis, "without regard to the political consequences."" Elmendorf told the Post that his office would provide the information, but the decision is in the hands of Congress. "CBO is not going to make or break health-care reform," he says.
News of the day
Skin And Skin Structure Infections Are The Second Most Common Diagnoses For Which An Antibiotic Is Used In The Hospital Setting
Arlington Medical Res (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the July - December 2008 time period, skin and skin structure infections continue to be the second most common diagnoses for which an antibiotic is used in the hospital setting. Antibiotic use for these infections is up 3 percent compared to the January - June 2008 time period. Lower respiratory infections continue to rank first with 29 percent of therapy courses even though this represents a 4 percent decrease from the previous audit period.
Nutrition

Quintiles Consulting Outlines Methods For Re-Balancing Drug Development Risks

Quintiles Consulting released the first in a three-part series of white papers addressing how best to navigate risk in drug development. The first paper, "On the Re-Balancing of Risk to Transform Cost and Productivity in Drug Development," focuses on operational risk. It is available for download at http://www.quintiles.com/consulting. Biopharmaceutical companies are facing unprecedented challenges in their efforts to bring new medicines to market to meet the needs of patients. Drug development costs are soaring - requiring on average nearly $1 billion and 17 years to bring a compound to market. It is well recognized in the industry that traditional cost-cutting and methods to improve productivity have been exhausted. "This new environment calls for novel risk-based solutions," said Adrian McKemey, Quintiles Consulting practice leader for product development and commercialization. "We are applying new business models to help companies rebalance, share and hedge their risk - transforming the traditional approach to development. The new risk-based approaches focus on ways to circumscribe, share, rebalance and hedge drug development risk to transform cost and productivity. "We are seeing risk being evaluated through three distinct lenses - operational risk, portfolio risk and re risk," McKemey said. The models outlined in the paper challenge and redistribute the traditional boundaries of the pharmaceutical business model, i.e., what a pharmaceutical company must own to capture competitive advantage and to grow, and what can be factored out and hedged by partnering with external s. The next paper in this series will focus on portfolio risk mitigation. To receive this paper or to learn more about Quintiles Consulting visit our website at http://www.quintiles.com/consulting. The authors: Adrian McKemey is a Managing Director with Quintiles Global Consulting (QGC) and leads the Product Development and Commercialization Practice. Badhri Srinivasan leads the Enterprise Transformation Unit - an organization dedicated to mining the experiences accumulated over 10,000 clinical trials to identify systematic issues and solutions increased speed and reduce cost and variance in clinical development. Peter Payne leads efforts on assessing, mitigating and pricing asset and clinical development risk to support risk sharing initiatives at the portfolio, operational and re level. About Quintiles Consulting Quintiles Consulting works with pharmaceutical, biotech and medical device companies to maximize potential and minimize risk, from discovery through development and commercialization by providing expert strategic, operational, and technical advice. Building on the global reach and expertise of Quintiles Transnational, Quintiles Consulting practice areas include Product Development and Commercialization, Regulatory and Quality, and Market Access, and Eidetics. Quintiles Consulting has full-time consultants based across the U.S. and Europe to serve its global clients. For more information, please visit http://www.quintiles.com/consulting. Quintiles


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009